Archrock, Inc. outlines the expected $18 million EBITDA reduction in 2026 stemming from asset sales in late 2025, detailing its quarterly flow and mitigating factors.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
How do you expect the $18 million EBITDA reduction from asset sales to flow through quarterly in 2026?
Analysis of the $18 Million Adjusted EBITDA Reduction from Asset Sales in 2026 and Its Quarterly Flow
Archrock, Inc. (AROC) expects an approximately $18 million reduction in adjusted EBITDA in 2026 attributable to asset sales executed primarily at the end of 2025. This drag reflects the fact that assets sold—amounting to 325,000 horsepower sold in total during 2025, with 175,000 being active horsepower—will no longer contribute to earnings in 2026. Of the $18 million adjusted EBITDA reduction, around $12 million is related to horsepower recently sold and announced alongside the 2025 year-end results, which has not yet been fully modeled into forward estimates and analyst forecasts 12.
How this EBITDA reduction flows quarterly in 2026:
Timing of Sold Assets and Impact on EBITDA:
Seasonality and Fleet Utilization:
Quarterly Cadence of Earnings Impact:
Summary:
| Factor | Details | Citation |
|---|---|---|
| Total estimated EBITDA reduction | ~$18 million for 2026 due to asset sales in late 2025 | 12 |
| Portion related to late 2025 sales | ~$12 million of the $18 million is from horsepower sold late | 1 |
| Quarterly flow | Evenly distributed across all quarters of 2026 | Implied from fleet utilization and sale timing 24 |
| Fleet utilization | Stable >95%, supporting steady EBITDA contribution | 2 |
| Offset from growth CapEx | 170,000 horsepower additions expected; 60% in first half | 4 |
| Resulting impact | EBITDA decline from asset sales should slightly taper as growth horsepower ramps but mainly spread over all quarters | Analytical inference |
Conclusion:
The $18 million EBITDA reduction due to asset sales is expected to flow through the 2026 quarters roughly evenly, starting fully in Q1, as these assets were sold late 2025 and thus generate no EBITDA in 2026. Some mitigation occurs via new horsepower additions, particularly in the first half of the year, but the net effect is a roughly $4.5 million quarterly EBITDA reduction that investors should model into their 2026 quarterly forecasts for Archrock. The company's strong fleet utilization and steady demand underpin a stable EBITDA contribution from the remaining and new assets, making the impact of the asset sales a clear and predictable deduction from the EBITDA baseline 124.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Archrock chose to maintain their full-year guidance despite strong Q1 results, citing seasonality, timing effects, and existing risks. This reflects a cautious, strategy-driven approach to forecasting.
Sources used
Research questionWhy did management choose not to raise full-year guidance after a strong Q1?
Answer outline
Cencora reports approximately 7% core growth in Q2 2026, suggesting underlying performance remains within its long-term framework despite WAC/IRA headwinds and customer losses. Management trimmed fiscal 2026 revenue guidance to 4-6%, but maintains a resilient long-term operating-income outlook supported by margin gains from mail-order conversions and ongoing OneOncology integration.
Sources used
Research questionWhat is the impact on long-term revenue and operating income growth from WAC/IRA adjustments, the loss of the oncology and grocery customers, and faster brand conversions at the large mail-order customer, given the reported core growth near 7%?
Answer outline
Twin Eagle's roughly $200 million base EBITDA is anchored in origination and logistics optimization rather than asset ownership. The earnings base appears repeatable under normal market conditions, with upside potential in volatile periods when dislocations boost margins. The expansion with Expand is expected to lift annual earnings toward the mid- to high-$300 millions within the next two years, supported by a large, high-retention customer base and recurring commercial relationships.
Sources used
Research questionWhat drives Twin Eagle's $200 million EBITDA—origination versus storage/transit spreads—and what is the expected year-to-year variability?
Answer outline
Peet's K-Cups shifts from U.S. Coffee to JDE Peet’s following the April close distort Q2 segment comparisons by moving Peet’s economics into the JDE Peet’s segment and making U.S. Coffee appear weaker. Management expects the back-half reversal to be neutral for enterprise earnings, with U.S. Coffee benefiting and JDE Peet's facing a corresponding headwind, and notes the Q2 result may represent a 2026 high-water mark for JDE Peet’s.
Sources used
Research questionHow did the acquisition-related reporting shift for Peet’s K-Cups between U.S. Coffee and JDE Peet’s affect Q2 segment comparisons, and what does management expect for the back-half earnings impact at the enterprise level?
Answer outline
TransDigm Group reports year-to-date margin pressure from acquisition-related dilution exceeding 200 basis points, with Q3 EBITDA margin at 52.8% and a conservative Q4 outlook as acquisitions remain early in ownership. Management maintains a modest, constant-mix margin improvement target of roughly 1% to 1.5% year over year, while noting only small mix headwinds and ROE-related headwinds without quantifying them.
Sources used
Research questionWhat is the year-to-date margin performance and what is expected for Q4 margins given acquisitions' dilution and mix and ROE-related headwinds?
Answer outline
Mastercard management expects Q3 rebates to be slightly higher than Q2 as a share of network assessments, driven by timing and deal performance, with a strong deal pipeline supporting execution. The BVNK acquisition is anticipated to close in Q3 with minimal net revenue impact but some operating expense, highlighting ongoing concentration on future flexibility.
Sources used
Research questionWhat did management say about Q3 rebates and incentives outlook?
Answer outline
Martin Marietta raises 2026 revenue guidance to 7.2B–7.4B, aided by New Frontier and Quikrete contributions; management expects a cleaner back half as fair-value step-ups fade and volumes remain strong.
Sources used
Research questionWhat are the puts and takes behind the updated 2026 revenue guidance, including contributions from New Frontier and Quikrete, and related margins and pace?
Answer outline
Amphenol's raised guidance for the CommScope acquisition points to a profitability path built on operating leverage and disciplined cost management rather than a simple top-line boost. The company emphasizes that the margin uplift derives from higher sales conversion, SG&A and Opex discipline, and operational execution, with acquisition-related amortization still leaving the business with a strong, mid-20s percent operating margin on an overall basis.
Sources used
Research questionWalk through the margin and earnings upside from the CommScope acquisition: is the improvement driven by operating leverage, gross margin expansion, or other factors, and how does amortization affect profitability outlook?
Answer outline
Aon plc reports Q2 2026 Commercial Risk growth was restrained by M&A services, with organic revenue up 5% as the quarter faced a headwind from muted M&A activity. Management signaled a stronger second-half pipeline, noting >60% higher announced transaction volumes and that M&A should become a tailwind for the year, supporting the company’s mid-single-digit organic growth guidance and improved visibility into full-year revenue.
Sources used
Research questionHow large was the M&A services drag in Commercial Risk in Q2, and what is the expected contribution from the stronger second-half pipeline to full-year growth?
Answer outline
Thermo Fisher's Q2 2026 results show a mixed yet constructive performance: Clario boosts reported growth via acquisitions (not organic), Patheon posts modest gains with a timing-driven second-half uplift, and PPD demonstrates strong clinical-research momentum despite a six-month authorization-to-revenue lag. Management reaffirmed guidance as acquisitions bolster full-year results across segments and supports guidance improvements.
Sources used
Research questionCould you share more color on PPD, Clario, and Patheon performance in Q2, including bookings, revenue growth, and contribution to the overall results?
Answer outline
TransDigm's management indicates the destocking noise in distribution is largely behind them, with POS signals supporting a tailwind as inventories clear. They outline a margin framework beyond 2026, highlighting near-term dilution from acquisitions but a continued base-margin expansion through 2027–2028 as integration progresses.
Sources used
Research questionIs the channel destock ending and how will margins evolve beyond 2026, including potential expansion in 2027–2028 amid acquisitions?
Answer outline
Elevance Health outlines a cautious 2H 2026 outlook for Medicaid, keeping the full-year margin at -1.75% and signaling only incremental improvement in the back half as rate updates and cost actions mature. Exits from markets lacking sustainable economics, including a DC exit and 12–18 month plans for additional markets, are framed as portfolio discipline rather than a driver of the near-term margin.
Sources used
Research questionGiven the Medicaid margin trajectory, quantify the potential exits relative to the $57 billion Medicaid revenue run rate and clarify whether exits are driven by work requirements or other state discussions, and how the second-half margin may differ?
Answer outline
Dafinchi